These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17383421)

  • 1. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
    Hofmann WP; Polta A; Herrmann E; Mihm U; Kronenberger B; Sonntag T; Lohmann V; Schönberger B; Zeuzem S; Sarrazin C
    Gastroenterology; 2007 Mar; 132(3):921-30. PubMed ID: 17383421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
    Mihm U; Hofmann WP; Welsch C; Polta A; Lengauer T; Zeuzem S; Sarrazin C; Herrmann E
    J Viral Hepat; 2010 Mar; 17(3):217-21. PubMed ID: 19758279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.
    Asahina Y; Izumi N; Enomoto N; Uchihara M; Kurosaki M; Onuki Y; Nishimura Y; Ueda K; Tsuchiya K; Nakanishi H; Kitamura T; Miyake S
    J Hepatol; 2005 Oct; 43(4):623-9. PubMed ID: 16098627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
    Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
    Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
    Quiles-Pérez R; Muñoz-de-Rueda P; Maldonado AM; Martín-Álvarez A; Quer J; Salmerón J
    J Med Virol; 2014 Nov; 86(11):1886-97. PubMed ID: 25091333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
    Lutchman G; Danehower S; Song BC; Liang TJ; Hoofnagle JH; Thomson M; Ghany MG
    Gastroenterology; 2007 May; 132(5):1757-66. PubMed ID: 17484873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
    Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
    Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
    J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    Saito Y; Imamura M; Uchida T; Osawa M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Serikawa M; Aikata H; Abe-Chayama H; Hayes CN; Chayama K
    J Med Virol; 2020 Feb; 92(2):210-218. PubMed ID: 31584207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
    Querenghi F; Yu Q; Billaud G; Maertens G; Trépo C; Zoulim F
    J Viral Hepat; 2001 Mar; 8(2):120-31. PubMed ID: 11264732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
    J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.